Lilly Direct vs LillyDirect Self-Pay: UK Patient Guide

Lilly Direct vs LillyDirect self-pay is a comparison many UK patients are searching for after encountering the US-based LillyDirect platform online. In the United States, LillyDirect offers a self-pay route to certain Eli Lilly medicines via independent telehealth providers. In the UK, the model is fundamentally different: since June 2026, LillyDirect operates solely as a dispensing and delivery service for privately prescribed Mounjaro (tirzepatide), not as a direct-purchase portal. Understanding this distinction is essential for anyone considering self-pay access to tirzepatide in the UK, both to protect their safety and to navigate the regulated private healthcare system correctly.

What Is Lilly Direct and How Does It Work in the UK?

LillyDirect in the UK is a dispensing and delivery service — not a self-pay portal — that fulfils privately prescribed Mounjaro through regulated pharmacy partners; a UK-registered prescriber must issue the prescription first.

Lilly Direct (styled LillyDirect) is a patient-access platform from Eli Lilly and Company, best known in recent years for tirzepatide and dulaglutide (Trulicity). In the United States, LillyDirect connects patients to independent telehealth providers and pharmacies and offers certain Lilly medicines on a self-pay basis; Eli Lilly does not itself make clinical decisions or dispense medicines directly to patients.

For UK readers, the position has recently changed. LillyDirect did not operate in the UK when it first launched, but since around 25 June 2026 a UK service exists. It is not a copy of the US model. In the UK, a manufacturer cannot sell prescription-only medicines directly to patients, so LillyDirect operates only as a dispensing and delivery service: a UK-regulated healthcare provider must first issue a private prescription for Mounjaro, and Lilly's UK dispensing partners (at launch, Pharmacy2U and Onescript) then fulfil and deliver it. There is no US-style 'self-pay counter' run by Lilly in the UK, so the cost of treatment is still set by the prescribing service and the pharmacy.

This distinction matters for patient safety. Some UK patients search for 'LillyDirect' after seeing the US service online and hope to find a similar direct-access or self-pay route. Others may encounter spoof or impersonation websites that misuse the LillyDirect name to sell unlicensed or counterfeit products. Buying medicines outside regulated UK channels carries significant risks, including falsified, counterfeit, or unlicensed products.

If you are in the UK and want to access tirzepatide (sold here as Mounjaro, for both type 2 diabetes and weight management), the appropriate route is through a registered UK prescriber, either via the NHS or a regulated private clinic. The MHRA provides guidance on buying medicines safely online, and you can verify that a pharmacy is registered via the General Pharmaceutical Council (GPhC) online register (Great Britain) or the Pharmaceutical Society of Northern Ireland (PSNI) register (Northern Ireland).

Self-Pay Options: Costs, Eligibility and What to Expect

Self-pay access to Mounjaro requires a licensed UK prescriber and a GPhC-registered pharmacy; private prescribing follows SmPC eligibility thresholds, which are broader than the more restrictive NHS NICE TA1026 criteria.

For UK patients who do not qualify for NHS-funded treatment, or who prefer to pay privately, self-pay routes exist, but they must always go through a licensed prescriber and a registered pharmacy. The most commonly sought self-pay medicine in this area is Mounjaro (tirzepatide), the single UK brand of tirzepatide, which holds MHRA authorisation for both type 2 diabetes and chronic weight management. (There is no separate UK brand for the weight-management indication: Zepbound, the brand used for weight management in the US, is not licensed or available in the UK.)

Because it is one product with two licensed indications, the same medicine, Mounjaro, is prescribed whether the clinical reason is diabetes or weight management. Your prescriber will confirm the indication and dose that fit your circumstances.

The cost of self-pay tirzepatide in the UK varies with the dose and the provider. Prices change and differ between pharmacies, so ask for a full breakdown before proceeding. Typical costs include:

• Consultation fees with a private GP or specialist

• Prescription and dispensing costs, which vary by pharmacy and dose (this now includes the option of delivery through UK LillyDirect's dispensing partners, though many other GPhC-registered pharmacies dispense Mounjaro too)

• Ongoing monitoring costs, since responsible prescribers require regular follow-up

Ask for transparent pricing with no hidden fees, and be cautious of unusually low prices.

Eligibility for self-pay prescribing is a clinical decision and should be distinguished from NHS funding criteria:

• The UK Summary of Product Characteristics (SmPC) for tirzepatide as a weight-management medicine covers adults with an initial BMI of at least 30 kg/m², or at least 27 kg/m² (and below 30) with at least one weight-related comorbidity. These licence thresholds apply to private prescribing.

• NICE technology appraisal TA1026 sets more restrictive criteria for NHS funding: a BMI of at least 35 kg/m² with at least one weight-related comorbidity (with a lower threshold for some ethnic groups), delivered through specialist services and phased in over several years. NHS eligibility is therefore narrower than the licence.

• NHS availability also varies by Integrated Care Board in England, or Health Board in Scotland and Wales; check with your GP or local service.

Key contraindications and precautions per the UK SmPC include:

• Pregnancy and breastfeeding: tirzepatide should not be used; women of childbearing potential should use effective contraception.

• History of pancreatitis or severe gastrointestinal disease: requires careful clinical assessment before prescribing.

• A point that differs from the US: a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) is a contraindication in the US label, but is not listed as a contraindication (or as a specific warning) in the UK/EU Mounjaro SmPC, where the only contraindication is hypersensitivity. Patients with thyroid concerns should still discuss them with their prescriber.

Avoid any platform that offers prescription medicines without a proper clinical consultation. UK clinical providers are regulated by the Care Quality Commission (CQC) in England, Healthcare Improvement Scotland (HIS) in Scotland, Healthcare Inspectorate Wales (HIW) in Wales, and the Regulation and Quality Improvement Authority (RQIA) in Northern Ireland. Verify that any provider is registered with the appropriate body before proceeding.

Safety, Regulation and MHRA Considerations for Self-Pay Medicines

The MHRA has authorised Mounjaro and issued alerts about counterfeit injectable weight-loss medicines; patients must use regulated providers and can report adverse reactions via the MHRA Yellow Card Scheme.

The Medicines and Healthcare products Regulatory Agency (MHRA) ensures that medicines are safe, effective, and of acceptable quality. All medicines legally supplied in the UK, on the NHS or privately, must hold a valid UK marketing authorisation or be supplied under a recognised exemption. Mounjaro (tirzepatide) holds full MHRA authorisation, having undergone rigorous clinical evaluation. (Zepbound, by contrast, is authorised in the US but not in the UK, which is why it should not be sourced or imported here.)

A key safety concern in the self-pay landscape is the growth of unregulated online sellers offering injectable medicines such as tirzepatide or semaglutide without a valid prescription. The MHRA has issued safety alerts about counterfeit and falsified weight-loss injections in the UK, some containing incorrect doses, unlicensed substances, or no active ingredient at all.^[12] Patients using unverified sources risk treatment failure and serious harm.

The following adverse effects are associated with tirzepatide, based on the UK SmPC. Frequencies reflect SmPC classifications:

• Very common (more than 1 in 10 people): nausea, vomiting, diarrhoea, decreased appetite, particularly during dose escalation

• Common (up to 1 in 10 people): increased heart rate, injection-site reactions, fatigue, constipation, dyspepsia, abdominal discomfort

• Uncommon to rare but clinically important: acute pancreatitis, gallbladder disease (including cholelithiasis and cholecystitis)

Additional safety considerations per the UK SmPC include:

• Hypoglycaemia: the risk rises when tirzepatide is used with insulin or a sulfonylurea; dose reduction of the concomitant medicine may be needed.^[1][8]

• Diabetic retinopathy: rapid improvement in blood glucose has been associated with worsening retinopathy; patients with a history of it should be monitored.

• Dehydration and acute kidney injury: persistent vomiting or diarrhoea can cause dehydration; maintain fluid intake and seek advice if symptoms are severe or prolonged.

• Pregnancy and breastfeeding: do not use; women planning pregnancy should stop treatment in advance, as advised by their prescriber.^[1][7]

Patients should contact their prescriber or GP promptly for severe or persistent abdominal pain, persistent vomiting, signs of dehydration, or signs of an allergic reaction.

All patients and healthcare professionals are encouraged to report suspected adverse reactions via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk), which supports ongoing post-marketing safety monitoring. Choosing a regulated provider ensures adverse events are properly documented and managed.

How to Access Lilly Medicines Safely as a Private Patient

Safe private access to Mounjaro begins with a consultation with a GMC- or NMC-registered prescriber and a pharmacy verified on the GPhC or PSNI register, with ongoing monitoring built into the care pathway.

If you are a UK patient considering self-pay access to Mounjaro or another Lilly medicine, the safest pathway starts with a consultation with a registered healthcare professional. This may be your NHS GP, who can advise on suitability and, in some cases, initiate a private prescription, or a private clinic registered with the relevant regulator for your nation that specialises in weight management, diabetes, or endocrinology.

When choosing a private provider, look for:

• Registration with the appropriate clinical regulator: CQC (England), HIS (Scotland), HIW (Wales), or RQIA (Northern Ireland)

• GPhC registration for any pharmacy dispensing your prescription (Great Britain), or PSNI registration (Northern Ireland). Since June 2026 this can include delivery via Eli Lilly's own LillyDirect dispensing partners, but the same registration checks apply

• A prescriber registered with the General Medical Council (GMC), Nursing and Midwifery Council (NMC), or other relevant body, all subject to standards for safe prescribing (including remote prescribing) set out in GMC guidance

• A clear process for ongoing monitoring and follow-up, not just a one-off prescription

• Transparent pricing with no hidden fees

NICE has published technology appraisal guidance on tirzepatide for managing overweight and obesity (TA1026) within specialist weight management services in England, and separately for type 2 diabetes (TA924). NHS availability is subject to local commissioning by Integrated Care Boards in England and Health Boards in Scotland and Wales, so speak with your GP about whether you may qualify for NHS-funded treatment before committing to self-pay costs.

In summary, LillyDirect now exists in the UK, but only as a dispensing and delivery layer for privately-prescribed Mounjaro, not as a US-style self-pay portal, and the concept of buying directly from the manufacturer at a set self-pay price does not apply here. UK patients do have legitimate, regulated routes to access Mounjaro privately. The guiding principle is always to work within the regulated UK healthcare system, protecting both your safety and your legal rights. Useful first points of reference include:

• MHRA: guidance on buying medicines safely online and safety alerts (gov.uk/mhra)

• GPhC pharmacy checker: to verify registered pharmacies in Great Britain (pharmacyregulation.org)

• PSNI register: to verify registered pharmacies in Northern Ireland (psni.org.uk)

• CQC, HIS, HIW, RQIA: to verify registered clinical providers across the UK

• GMC and NMC registers: to verify your prescriber

• MHRA Yellow Card Scheme: to report suspected adverse reactions (yellowcard.mhra.gov.uk)

Scientific References

1. Mounjaro KwikPen 2.5 mg solution for injection in pre-filled pen — UK Summary of Product Characteristics.
2. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
3. Tirzepatide for treating type 2 diabetes (TA924).
4. Tirzepatide for managing overweight and obesity (TA1026).
5. Tirzepatide for managing overweight and obesity — Recommendations (TA1026, Chapter 1).
6. Tirzepatide local formulary information (TA1026).
7. A practical guide to using medicines to manage overweight and obesity — Prescribing, reviewing and stopping tirzepatide (TA1026).
8. Tirzepatide — BNF monograph.
9. Mounjaro (tirzepatide) — EPAR product information.
10. Mounjaro — European Medicines Agency medicine page.
11. Mounjaro EU Risk Management Plan (Version 2.1).
12. MHRA warns of unsafe fake weight loss pens.
13. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease).
14. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
15. Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.
16. Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study.

Frequently Asked Questions